Chemomab Therapeutics Ltd. and Scipher Medicine Corporation have entered into an all-stock merger agreement to create a Nasdaq-listed precision immunology company focused initially on nebokitug, a first-in-class anti-CCL24 antibody planned for a Phase 2 rheumatoid arthritis trial. The combined company is expected to operate as Scipher Medicine Corporation and trade under the ticker symbol SCIP,
SOPHiA GENETICS and Memorial Sloan Kettering aim to turn cancer data into precision oncology infrastructure. Can the hub deliver?
Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.
Find out why Seer’s activist battle could reshape investor thinking on proteomics, diagnostics platforms and biotech value creation.
ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.
Medtech suppliers are under pressure to prove growth quality. Novanta’s Jefferies appearance may sharpen the investor debate.
Pharma has too much data and too little time. AstraZeneca’s Owkin deal tests whether agentic AI can sharpen drug development decisions.
Ultra-rare epilepsy has few paths forward. Actio’s ABS-1230 now tests whether precision genetics can reshape FDA evidence standards.
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.